Navigation Links
Jefferson researchers study outcomes of carotid artery stenting following prior carotid procedure
Date:11/14/2011

PHILADELPHIA A new study shows that carotid artery stenting (CAS) following prior same-side carotid artery revascularization is safe, effective and results in lower incidences of in-hospital death, stroke and heart attack compared to first-time CAS for carotid artery stenosis.

This study received "Best of Session" recognition and will be presented in an abstract format at the American Heart Association annual meeting on November 14 at 9:30 AM in Orlando, FL.

"The optimal management of carotid artery stenosis following prior revascularization is unclear in the available literature," said Nicholas J. Ruggiero, II, M.D., F.A.C.C., F.S.C.A.I., F.S.V.M., director of Structural Heart Disease and Non-Coronary Interventions at the Jefferson Heart Institute and assistant professor of Medicine, Jefferson Medical College of Thomas Jefferson University, second author.

"This is the largest study to show that carotid artery stenting after prior revascularization has better outcomes for the patient than previously thought possible."

The carotid artery is the main blood vessel carrying oxygenated blood to the brain. It can become narrowed or blocked as a result of plaque build-up from cholesterol, cellular waste products, calcium, and fibrin in the inner lining of an artery or atherosclerosis, or "hardening of the arteries". Carotid artery endartectomy (CEA), surgical removal of arterial plaque and stenting (CAS) are often used to treat carotid artery stenosis and are key in stroke prevention.

The team retrospectively analyzed and compared NCDR CARE registry data. They reviewed patient and procedural characteristics and clinical outcomes of patients undergoing CAS after prior same-side CEA or CAS with those who had CAS performed one-time for carotid artery stenosis and found a lower rate of in-hospital death, stroke and heart attack in the former.

"These findings have the potential to bring about significant c
'/>"/>

Contact: Lee-Ann Landis
leeann.landis@jefferson.edu
215-459-2092
Thomas Jefferson University
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Jefferson is first academic medical center to offer FDA-approved BRAF mutation for melanoma patients
2. Thomas Jefferson University Hospital cuts Whipple procedure wound infections in half with new measures
3. Jefferson physician named an Educator of the Year by the Assocociation of Residents in Radiation Oncology
4. Thomas Jefferson University Hospital adopts new imaging agent to improve detection of bladder cancer
5. Thomas Jefferson University and hospitals tasked to find new radiation drugs
6. FDA approval of brain aneurysm device gives Jefferson neurosurgeons another life-saving tool
7. Jefferson doctors strengthen case for high-dose radiotherapy technique after radical prostatectomy
8. Kimmel Cancer Center at Jefferson breast cancer symposium features latest in research, treatment
9. Jefferson clinical trial: Can a cholesterol drug prevent colon cancer?
10. Thomas Jefferson University professor elected AAAS Fellow
11. Jefferson study determines bone marrow stromal stem cells may aid in stroke recovery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2014)... 27, 2014 Tylenol lawsuits ( http://www.tylenollawsuitcenter.com/ ... injured by the medication are continuing to move forward ... looking ahead to a status conference in December, Bernstein ... Order issued earlier this year, a conference in the ... 10:00 a.m. Items likely to be discussed at the ...
(Date:11/27/2014)... Washington, DC (PRWEB) November 27, 2014 “LAB.C” ... Report, which features the latest and coolest technology products available ... NewsWatch, conducted the product review and shared with ... cable for iOS and Android devices. , Consumers love portability ... LAB.C. Their Cable Case for the iPhone5 and 5S ...
(Date:11/27/2014)... 27, 2014 HealthPostures, a ... equipment , has announced that it has entered ... Environments. The partnership will put HealthPostures' products into ... , In addition to having its products sold ... promotes HealthPostures' products with the business decision makers ...
(Date:11/27/2014)... 2014 "The uglier, the better," says Dr. ... is full of laughter as we enjoy the ugly sweater ... a sweater from scratch. " It was a sight to ... that weren't ridiculous enough, the Christmas balls were faces of ... those interested in participating this year, it's simple to get ...
(Date:11/27/2014)... November 27, 2014 Ethane Web Technologies, an ... will provide a 10% Christmas discount on PPC service. The ... The discount offer will begin on 1 December 2014 and ... About this offer, a PPC professional working at Ethane Web ... for small businesses, as this big discount would make the ...
Breaking Medicine News(10 mins):Health News:Federal Litigation Presiding over Tylenol Lawsuits Looks Ahead to Status Conference in December, Bernstein Liebhard LLP Reports 2Health News:Federal Litigation Presiding over Tylenol Lawsuits Looks Ahead to Status Conference in December, Bernstein Liebhard LLP Reports 3Health News:Top Mobile Friendly Accessories were Featured on NewsWatch Television on October 30, 2014 2Health News:Ergonomics Manufacturer Announces New Partnership with Office Supply Dealer 2Health News:Verde Pointe Dental Associates Hosts 2014 Ugly Holiday Sweater Contest 2Health News:Verde Pointe Dental Associates Hosts 2014 Ugly Holiday Sweater Contest 3Health News:Ethane Web Technologies Announces 10% Christmas Discount on PPC Service 2
... to a hundred years ago are being used in the ... the first time old bones have been used in this ... combination of latest computer modelling techniques developed at the University ... of Bristol. With Engineering and Physical Sciences Research Council ...
... core professional obligation and lying, even for a patient, ... Jr., MD, FACP, president of the American College of ... internal medicine physician and medical student members today. ... "sick notes" issued without a medical evaluation to some ...
... HealthDay Reporter , MONDAY, Feb. 28 (HealthDay News) ... in which inflammation of the lining of the nose and ... the most severe cases, patients develop nasal polyps that can ... to begin with a steroid nasal spray and then move ...
... , MONDAY, Feb. 28 (HealthDay News) -- Few things send ... rising temperature. But, a new report from the American ... reminding parents that a fever is usually just the body,s ... actually prolong an illness. The AAP recommends that, in ...
... , MONDAY, Feb. 28 (HealthDay News) -- Heart ... positive outlook, researchers are reporting. More than 2,800 heart ... their belief in their ability to recover from the illness ... 1,637 of the patients had died. Of those deaths, 885 ...
... MONDAY, Feb. 28 (HealthDay News) -- The stress of ... and gain weight, researchers report. The Georgia Health ... 60 first-time mothers who were asked about their levels ... a low amount of physical activity, was most influenced ...
Cached Medicine News:Health News:Learning from old bones to treat modern back pain 2Health News:For Severe Sinusitis, Oral Steroids an Option, Study Says 2Health News:For Severe Sinusitis, Oral Steroids an Option, Study Says 3Health News:Kids' Fevers May Not Always Need Treatment 2Health News:Kids' Fevers May Not Always Need Treatment 3Health News:Stress May Help Spur Weight Gain in New Moms, Study Finds 2
(Date:11/26/2014)... 25, 2014  Array BioPharma Inc. (Nasdaq: ... its Chief Executive Officer, Ron Squarer ... conferences.  The public is welcome to participate ... Array BioPharma website:  www.arraybiopharma.com .Event: Piper Jaffray ...  Eastern Time Location: Palace Hotel, New York ...
(Date:11/26/2014)... and LONDON , Nov. 25, ... AstraZeneca (NYSE: AZN ) today announced that AMAGINE-2 ... doses of brodalumab in more than 1,800 patients with moderate-to-severe ... Stelara ® (ustekinumab) and placebo at week 12. Brodalumab ... analysis group were each shown to be superior to Stelara ...
(Date:11/26/2014)... YORK and HERZLIYA PITUACH, Israel, Nov. 25, ... "Immune" or "the Company"), a clinical stage biopharmaceutical ... of targeted therapeutics for the treatment of inflammatory ... its previously announced underwritten public offering of 3,450,000 ... of the Company,s common stock, par value $0.0001 ...
Breaking Medicine Technology:Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 2Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 3Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 4Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 5
... GRONINGEN, Netherlands , July 26 ... organization providing testing services to support preclinical and clinical ... of Xendo Drug Development BV (XDD), headquartered in Groningen, ... organization (CRO), will be known as QPS Netherlands BV ...
... Harco Metal Products (Harco), an industry leader in tube ... contract to manufacture MediGLIDER™ products for ConMediSys. , ... ConMediSys, the developer of safety products ... risk and cost associated with staff injuries caused by physically lifting ...
Cached Medicine Technology:QPS Announces the Acquisition of Xendo Drug Development 2QPS Announces the Acquisition of Xendo Drug Development 3QPS Announces the Acquisition of Xendo Drug Development 4Harco Partners With ConMediSys to Deliver Patient Safety and Equipment Integrity 2
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Medicine Products: